Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/587
Type: Artigo de periódico
Title: Pregnancy outcome in juvenile systemic lupus erythematosus: A Brazilian multicenter cohort study
Author: SILVA, Clovis A. A.
HILARIO, Maria O.
FEBRONIO, Marilia V.
OLIVEIRA, Sheila K.
ALMEIDA, Rozana G.
FONSECA, Adriana R.
YAMASHITA, Edson M.
RONCHEZEL, Marcos V.
CAMPOS, Luciene L.
APPENZELLER, Simone
QUINTERO, Maria V.
SANTOS, Ana B.
MEDEIROS, Ana C.
CARVALHO, Luciana M.
ROBAZZI, Teresa C.
CARDIN, Silvana P.
BONFA, Eloisa
Abstract: Objective. To determine pregnancy outcome and fetal loss risk factors in patients with juvenile systemic lupus erythematosus (JSLE). Methods. A total of 315 female patients with JSLE followed in 12 Brazilian pediatric rheumatology centers were consecutively selected. Menarche was observed in 298 (94.6%) patients. Patients` medical records were reviewed for pregnancy outcomes and demographic, clinical, and therapeutic data. Results. A total of 24 unplanned pregnancies occurred in 298 (8%) patients. The outcomes were 5 (21%) early fetal losses (prior to 16 wks gestation), 18 (75%) live births, and 1 (4%) death due to preeclampsia and premature birth. The frequencies of active diffuse proliferative glomerulonephritis, proteinuria >= 0.5 g/day, and arterial hypertension at the beginning of pregnancy were higher in pregnancies resulting in fetal losses than in live births [60% vs 5% (p = 0.02), 60% vs 5% (p = 0.02), 60% vs 5% (p = 0.02), respectively]. JSLE pregnancies with fetal losses had a significantly higher mean SLE Disease Activity Index 2000 (SLEDAI-2K) at the start of pregnancy compared with those with live births (9.40 +/- 7.47 vs 3.94 +/- 6.00; p = 0.049). Four pregnancies were inadvertently exposed to intravenous cyclophosphamide therapy for renal involvement despite contraceptive prescriptions, resulting in fetal loss in 3 (p = 0.02). In multivariate analysis only intravenous cyclophosphamide use at start of pregnancy (OR 25.50, 95% CI 1.72-377.93, p = 0.019) remained as an independent risk factor for fetal loss. Conclusion. We identified immunosuppressive therapy as the major contributing factor for fetal loss in JSLE, reinforcing the importance of contraception.
Subject: systemic lupus erythematosus
adolescent
outcome
pregnancy
fetal loss
cyclophosphamide
Country: Canadá
Editor: J RHEUMATOL PUBL CO
Rights: fechado
Address: http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&UT=000257554400033&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord
http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&UT=000257554400033&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord
Date Issue: 2008
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
art_SILVA_Pregnancy_outcome_in_juvenile_systemic_lupus_erythematosus_2008.pdfpublished version267.42 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.